Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 20/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795006 | 0.91 | PRMT5 (0.41) | PRMT5 | |
| Lithium Ion SCHEMBL6793825 | 0.87 | SMYD3 (0.32) | — | |
| Lithium Ion SCHEMBL6793578 | 0.85 | CARM1 (0.36) | PRMT5 | |
| Lithium Ion SCHEMBL6800533 | 0.79 | PRMT5 (0.35) | PRMT5 | |
| Lithium Ion SCHEMBL6787026 | 0.79 | ROCK2 (0.38) | PRMT5 | |
| Lithium Ion SCHEMBL6794513 | 0.79 | PRMT5 (0.35) | PRMT5 | |
| SCHEMBL6793835 | 0.79 | HRH1 (0.32) | — | |
| Lithium Ion SCHEMBL6791729 | 0.78 | ROCK2 (0.40) | — | |
| Lithium Ion SCHEMBL6792451 | 0.78 | AGER (0.35) | — | |
| Lithium Ion SCHEMBL6787009 | 0.77 | PRMT5 (0.37) | PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | PRMT5 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.